ArticleFrontiers in pharmacology2023
Reimbursement of pharmacogenetic tests at a tertiary academic medical center in the United States.
Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 28 citations in OpenAlex.
- Article
- Clinical Implementation of Pharmacogenomics and Drug-Drug Interaction Screening in a German Academic Teaching Hospital and Outpatient Follow-Up.Clinical pharmacology and therapeutics · 2026Article
- The critical need to implement pharmacogenomics in public health services: Mexico in the global picture.Frontiers in public health · 2026Article
- Strategic insights into pharmacogenomics coverage: a theory-informed SWOT analysis of UAE insurance stakeholders' perspectives.Human genomics · 2025Article
- The prevalence of pharmacogenetic testing in the United States.Pharmacogenetics and genomics · 2025Article
- Current State of Pharmacogenomic Implementation Into Care for Persons With Cystic Fibrosis.Pediatric pulmonology · 2025Article
- Analyzing pharmacogenetics cost effectiveness and savings across common health conditions in the United States.The pharmacogenomics journal · 2025Review
- Clinician Experiences at the Frontier of Pharmacogenomics and Future Directions.Journal of personalized medicine · 2025Article
- Pharmacogenetics: Opportunities for theAnnual review of pharmacology and toxicology · 2025Review
- Review
- Strategies for DPYD testing prior to fluoropyrimidine chemotherapy in the US.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Estimating preferences and willingness to pay for pharmacogenetic testing in populations who are medically underserved: a discrete choice experiment.Frontiers in pharmacology · 2024Article
- Lessons from clinical implementation of a preemptive pharmacogenetic panel as part of a testing pilot program with an employer-sponsored medical plan.Frontiers in genetics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.